TY - JOUR T1 - Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline? JF - medRxiv DO - 10.1101/2022.05.23.22275241 SP - 2022.05.23.22275241 AU - Rik Ossenkoppele AU - Alexa Pichet Binette AU - Colin Groot AU - Ruben Smith AU - Olof Strandberg AU - Sebastian Palmqvist AU - Erik Stomrud AU - Pontus Tideman AU - Tomas Ohlsson AU - Jonas Jögi AU - Keith Johnson AU - Reisa Sperling AU - Vincent Dore AU - Colin L. Masters AU - Christopher Rowe AU - Denise Visser AU - Bart N.M. van Berckel AU - Wiesje M. van der Flier AU - Suzanne Baker AU - William J. Jagust AU - Heather J. Wiste AU - Ronald C. Petersen AU - Clifford R. Jack, Jr. AU - Oskar Hansson Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/25/2022.05.23.22275241.abstract N2 - A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer’s disease (AD) neuropathological hallmarks (i.e., amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multi-center amyloid and tau PET study (n=1325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A+) and tau PET positive (T+) in the medial temporal lobe (A+TMTL+) and/or in the neocortex (A+TNEO+) and compared them with A+T- and A-T-groups. Cox proportional hazard models showed a substantially increased risk for progression to mild cognitive impairment in the A+TNEO+ (Hazard ratio [HR]=19.2[95% confidence interval: 10.9-33.7]), A+TMTL+ (HR=14.6[8.1-26.4) and A+T-(HR=2.4[1.4-4.3]) groups vs the A-T-(reference) group. Linear mixed effect models indicated that the A+TNEO+ (β=-0.056±0.005, T=-11.55, p<0.001), A+TMTL+ (β=-0.024±0.005, T=-4.72, p<0.001) and A+T-(β=-0.008±0.002, T=-3.46, p<0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A-T-(reference) group (all p<0.001). Evidence of advanced AD pathological changes provided by amyloid and tau PET is strongly associated with short-term (i.e., 3-5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation programme (grant agreement No. 949570, PI: Rik Ossenkoppele). Work at Lund University was supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinsons disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1280/20), the Konung Gustaf V och Drottning Victorias Frimurarestiftelse, the Skane University Hospital Foundation (2020-O000028), Regionalt Forskningsstod (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279). Acknowledgement is also made to the donors of the Alzheimers Disease Research, a program of the BrightFocus Foundation, for support of this research (A2021013F). APB is supported by a postdoctoral fellowship from the Fonds de recherche en Sante Quebec (298314). The precursor of 18F-flortaucipir was provided by AVID radiopharmaceuticals and the precursor of 18F-RO948 was provided by Roche. The precursor of 18F-flutemetamol was sponsored by GE Healthcare. The MCSA is supported by the National Institute on Aging, U01 AG006786, GHR and the Alzheimers Association. Research of Alzheimer center Amsterdam has been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer and Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). The funding sources had no role in the design and conduct of the study; in the collection, analysis, interpretation of the data; or in the preparation, review, or approval of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants. For MSCA, this study was approved by institutional review boards at the Mayo Clinic and Olmsted Medical Center (both Rochester, MS, USA). For the BioFINDER-1 and BioFINDER-2 studies, ethical approval was given by the Regional Ethical Committee in Lund, Sweden. For BACS, the Institutional Review Board at Lawrence Berkeley National Laboratory and the University of California Berkeley approved the study. The AIBL study was approved by institutional ethics committees of Austin Health, St. Vincent's health, Hollywood Private Hospital and Edith Cowan University. For HABS, the protocol was approved by the Partners Human Research Committee. For ADC, the study protocol was approved by the Medical Ethics Review Committee of the Amsterdam UMC, location VU Medical centerI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the multicentric design of the study, access to individual participant data from each cohort would have to be made available through the PIs of the respective cohorts. Generally, anonymised data can be shared by request from qualified academic investigators for the purpose of replicating procedures and results presented in the article, as long as data transfer is in agreement with the data protection regulation at the institution and is approved by the local Ethics Review Board. Requests for data from the open-access part of HABS can be submitted to: https://habs.mgh.harvard.edu. ER -